A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
about
Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral ControlUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsTargeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical ApproachesNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityAdvances in immunotherapy for treatment of lung cancerDevelopment of Novel Immunotherapies for Multiple MyelomaImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesImproving natural killer cell cancer immunotherapyRenal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Immune checkpoint blockade for hematologic malignancies: a reviewNK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.The head and neck cancer immune landscape and its immunotherapeutic implications.Role of Natural Killer Cells in HIV-Associated Malignancies.Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.Immunologic approaches for the treatment of multiple myeloma.Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies.Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Immunosenescence: limitations of natural killer cell-based cancer immunotherapy.Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionImmunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work.Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?Control of NK Cell Activation by Immune Checkpoint Molecules.Trial watch: Immune checkpoint blockers for cancer therapy.Innate immune cells for immunotherapy of autoimmune and cancer disorders.KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells.Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.Emerging immune targets for the treatment of multiple myeloma.A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies.The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.Tumor immunotherapy: New aspects of natural killer cells.Next generation immune-checkpoints for cancer therapy.Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer CellsUnchaining NK cell–mediated anticancer immunosurveillance
P2860
Q26747397-1205A1E9-0A34-4A2B-891F-35ED176736CBQ26751011-C0161F5A-2637-438C-B468-65E49B1C85A6Q26752518-69B845CD-04A0-44D7-A533-074513F755E4Q26773135-EE871C0F-CCA0-48E3-B490-2A0644CEC3A3Q26778790-988C8500-E811-44A3-A8BB-09727A27C8BFQ28066890-517627D7-1DAC-44CE-A923-39A7DE342953Q28079180-9F42F5E3-E1A4-4870-B6CC-9D865F5BB475Q28087719-D19BBB43-8CAD-4626-8758-F9451C0BD932Q30275870-6BC4DA19-ED20-4D55-A9A0-FF6C429C3265Q33645590-34A174A9-515A-4422-9138-F423AF5EAC81Q33798745-531E4FE9-C194-4B63-96AE-72C8116E2671Q36245682-3775D19E-0DC0-445D-930B-33705B78DDF6Q37351606-69284DFC-F1FF-432C-9BE6-D61BDE31612AQ37712593-20F5C655-6D5D-4B91-8BD6-A7B23486BE41Q38599353-D0130515-204B-4346-BF0A-EE2A198EA3BCQ38692244-1A129037-7390-47A1-B79A-63957129BA89Q38708402-3313EC45-901F-4728-AB35-4449E41945EFQ38737970-06A5F610-9708-40AF-8D1E-531CB8BA89F7Q38928938-DBE65678-5B1B-4F69-B3C2-F10F4943E430Q38958563-AB3D6321-BE7D-4626-A11E-4C878DD06F02Q39136762-0B4CBC8E-183F-4778-85DC-2E93CFCF1487Q39138108-483ED759-02B4-4B9C-856E-4C5A4150007BQ39174731-CB9AE4BC-0D22-419D-A7CF-B5A1947E6831Q41714691-55759FA2-B785-4455-AA08-A083A5D621E3Q42042886-598DAF73-01FD-42BA-90C2-7A1D5654CFA6Q42660142-31106CED-1488-4EE1-ABC8-E28F2D73EE6EQ42684464-C259CB23-309E-44EC-9468-8ABF4527F177Q47128718-6E0B4563-754C-431B-A8C9-8A727455E677Q47393365-8DED6CF0-32CD-4373-9C03-EDDDC92B8839Q48316500-71906AFC-BD71-4518-8A38-47D37B13A6E8Q48361273-0DEF0237-0771-4FC0-AE54-C7B5495CA759Q48590636-F5BDDA90-24ED-4B82-A9BC-1C83F2EB2CF6Q49830211-F9C0849B-6390-48F4-AFC6-4EF877D514AAQ50025144-4B3E0509-781B-41FD-A580-62BAE285D57CQ54943618-14C17C39-1A6A-4AF3-88B9-BA50A17A89C1Q55042057-4BFB4FA7-C45D-47F9-BDEC-02CB0273CB33Q55107050-B2321666-C395-469E-BF25-991AB3468234Q55383705-83E365C9-756B-4DF2-9448-23860471B294Q56889003-CD59DD4B-DC65-4F61-9BF7-4FFA6CF0601BQ57082741-9BE03FCF-6B25-4C4A-A3EA-CAFB7306C2CE
P2860
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@ast
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@en
type
label
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@ast
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@en
prefLabel
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@ast
A Phase I Trial of the Anti-KI ...... d/Refractory Multiple Myeloma.
@en
P2093
P2860
P1476
A Phase I Trial of the Anti-KI ...... ed/Refractory Multiple Myeloma
@en
P2093
Craig C Hofmeister
Don M Benson
Gary Spitzer
Michael A Caligiuri
Nikhil C Munshi
Pascale Andre
Robert Zerbib
Sundar Jagannath
Yvonne A Efebera
P2860
P304
P356
10.1158/1078-0432.CCR-15-0304
P407
P50
P577
2015-05-21T00:00:00Z